Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.99 USD
-0.12 (-1.96%)
Updated May 3, 2024 04:00 PM ET
After-Market: $6.02 +0.03 (0.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FHTX 5.99 -0.12(-1.96%)
Will FHTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Other News for FHTX
Analysts’ Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics appoints Kristian Humer as chief financial officer
Foghorn Therapeutics Appoints Kristian Humer as New CFO
Foghorn Therapeutics appoints Humer as Chief Financial Officer